Pharmacology & Toxicology

9 domain-specific abstractions whose origin domain is Pharmacology & Toxicology.

• Aspect Qualifier — Attach a controlled modifier from a small closed list to a subject descriptor so the indexed claim names a topic in one specific sense — Aspirin/adverse effects, not aspirin-as-such — factoring topic from aspect to gain precision without vocabulary bloat.
• Controlled Descriptor — Substitute one governed preferred term from a maintained vocabulary for whatever words a resource used, so every resource on a topic retrieves through the same descriptor regardless of the author's surface phrasing.
• Efficacy — Separate the maximum effect a drug can produce at its target under full engagement (the ceiling, E_max) from the dose needed to approach it (potency, EC50), rooting that ceiling in the agent's intrinsic activity so a ceiling problem cannot be fixed by escalation.
• Elimination Pathway — Classify a drug or toxin by the dominant biochemical route through which the body removes it — hepatic metabolism, renal excretion, or a minor exit — so that clearance rate, interaction risks, and toxicity failure modes can be read off the route rather than memorized per substance.
• Entry Term Alias — Curate a non-preferred surface form — synonym, abbreviation, colloquialism, superseded name — as a silent, non-indexing bridge that routes many-to-one to a canonical descriptor, so users arrive at one place however they name the concept.
• Inverse Agonist — A ligand that binds a receptor with constitutive activity and selectively stabilizes its inactive conformation, driving output below the unliganded baseline — occupying the negative end of a signed efficacy axis, distinct from an antagonist that merely blocks.
• NOAEL (No Observed Adverse Effect Level) — Anchor a substance's acceptable human exposure at the highest tested dose showing no observed adverse effect, treating that dose as a fact about the study's design that brackets — but does not pin — the unknown biological threshold.
• Partial Agonist — A ligand that binds and activates a receptor but with intrinsic efficacy between zero and one, so even at full occupancy it produces a submaximal response — acting as an agonist when alone and a functional antagonist when a full agonist is present.
• Polypharmacy — Shift the unit of clinical attention from the single prescription to the whole regimen, sorting the combined risk of concurrent drugs into three channels — pharmacokinetic collisions, pharmacodynamic summation, and the prescribing cascade — under one appropriate-versus-problematic binary.